| 451 |
18774637 | The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. | 2008 Dec 18 |
2 |
| 452 |
18803986 | Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. | 2008 Aug |
6 |
| 453 |
18823221 | Lapatinib and ixabepilone for the treatment of metastatic breast cancer. | 2008 Oct |
4 |
| 454 |
18829547 | Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. | 2008 Oct 1 |
3 |
| 455 |
18849320 | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. | 2008 Oct |
2 |
| 456 |
18952552 | Unraveling the biologic and clinical complexities of HER2. | 2008 Oct |
1 |
| 457 |
18955454 | Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. | 2008 Dec 1 |
1 |
| 458 |
19046108 | Jumping higher: is it still possible? The ALTTO trial challenge. | 2008 Dec |
1 |
| 459 |
19047149 | Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. | 2008 Dec 1 |
2 |
| 460 |
19562083 | EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. | 2008 Dec 9 |
1 |
| 461 |
19707428 | Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. | 2008 Mar |
2 |
| 462 |
21127749 | Targeted treatment of advanced and metastaticbreast cancer with lapatinib. | 2008 Sep 1 |
1 |
| 463 |
17060407 | Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. | 2007 Jan |
2 |
| 464 |
17203189 | Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. | 2007 Feb |
3 |
| 465 |
17208435 | Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). | 2007 Feb |
1 |
| 466 |
17250463 | Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. | 2007 Feb |
7 |
| 467 |
17283152 | Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. | 2007 Feb 1 |
2 |
| 468 |
17308062 | Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. | 2007 Feb |
4 |
| 469 |
17320695 | Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. | 2007 Feb |
2 |
| 470 |
17350323 | Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. | 2007 Sep |
1 |
| 471 |
17402790 | HER-2-positive breast cancer: hope beyond trastuzumab. | 2007 |
1 |
| 472 |
17485900 | Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? | 2007 |
2 |
| 473 |
17489737 | Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. | 2007 May |
1 |
| 474 |
17513611 | Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. | 2007 May |
4 |
| 475 |
17547474 | HER2-positive breast cancer: current and future treatment strategies. | 2007 |
1 |
| 476 |
17555368 | Her signaling in pancreatic cancer. | 2007 Jun |
1 |
| 477 |
17591827 | Lapatinib in breast cancer. | 2007 Jun |
3 |
| 478 |
17593621 | EGFR and HER-2 antagonists in breast cancer. | 2007 May-Jun |
1 |
| 479 |
17635524 | Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. | 2007 Aug |
12 |
| 480 |
17673607 | Lapatinib-associated toxicity and practical management recommendations. | 2007 Jul |
1 |
| 481 |
17699871 | Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. | 2007 Aug 15 |
1 |
| 482 |
17714070 | Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. | 2007 Sep |
1 |
| 483 |
17761983 | Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. | 2007 Sep 1 |
2 |
| 484 |
17827454 | Biology of interactions: antiepidermal growth factor receptor agents. | 2007 Sep 10 |
1 |
| 485 |
18472989 | A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. | 2007 Aug |
2 |
| 486 |
19707333 | Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. | 2007 Sep |
1 |
| 487 |
16397255 | Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. | 2006 Jan 1 |
2 |
| 488 |
16452222 | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. | 2006 Feb 1 |
4 |
| 489 |
16452223 | Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. | 2006 Feb 1 |
2 |
| 490 |
16894399 | Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. | 2006 Jul |
5 |
| 491 |
16934227 | Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. | 2006 Oct 16 |
1 |
| 492 |
16940802 | Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. | 2006 Sep |
1 |
| 493 |
17092403 | Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. | 2006 Oct |
2 |
| 494 |
17110623 | Lapatinib: current status and future directions in breast cancer. | 2006 Nov-Dec |
1 |
| 495 |
17192538 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer. | 2006 Dec 28 |
1 |
| 496 |
15528979 | Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. | 2005 Jan |
2 |
| 497 |
15665275 | The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. | 2005 Jan 1 |
4 |
| 498 |
15684311 | Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. | 2005 Apr 10 |
3 |
| 499 |
15755991 | Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. | 2005 Mar 1 |
3 |
| 500 |
15833875 | Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. | 2005 Apr 15 |
2 |